A detailed history of Citigroup Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 41,197 shares of RYTM stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,197
Previous 19,992 106.07%
Holding current value
$2.47 Million
Previous $820,000 163.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.81 - $55.0 $865,376 - $1.17 Million
21,205 Added 106.07%
41,197 $2.16 Million
Q2 2024

Aug 12, 2024

SELL
$35.41 - $44.37 $6.04 Million - $7.57 Million
-170,528 Reduced 89.51%
19,992 $820,000
Q1 2024

May 10, 2024

BUY
$39.12 - $52.44 $5.33 Million - $7.14 Million
136,220 Added 250.87%
190,520 $8.26 Million
Q4 2023

Feb 09, 2024

SELL
$21.39 - $49.64 $317,513 - $736,856
-14,844 Reduced 21.47%
54,300 $2.5 Million
Q3 2023

Nov 09, 2023

SELL
$15.81 - $27.8 $299,141 - $526,003
-18,921 Reduced 21.49%
69,144 $1.58 Million
Q2 2023

Aug 10, 2023

SELL
$16.32 - $21.15 $4.11 Million - $5.33 Million
-251,890 Reduced 74.1%
88,065 $1.45 Million
Q1 2023

May 11, 2023

BUY
$16.88 - $34.24 $1.09 Million - $2.2 Million
64,394 Added 23.37%
339,955 $6.06 Million
Q4 2022

Feb 09, 2023

BUY
$22.21 - $30.25 $74,936 - $102,063
3,374 Added 1.24%
275,561 $8.02 Million
Q3 2022

Nov 10, 2022

BUY
$4.3 - $30.85 $1.16 Million - $8.33 Million
269,921 Added 11911.78%
272,187 $6.67 Million
Q2 2022

Aug 10, 2022

SELL
$3.12 - $12.25 $7,069 - $27,758
-2,266 Reduced 50.0%
2,266 $9,000
Q1 2022

May 12, 2022

SELL
$6.13 - $12.24 $560,803 - $1.12 Million
-91,485 Reduced 95.28%
4,532 $52,000
Q4 2021

Feb 10, 2022

BUY
$8.62 - $13.9 $312,828 - $504,444
36,291 Added 60.76%
96,017 $958,000
Q3 2021

Nov 10, 2021

BUY
$11.68 - $20.72 $697,599 - $1.24 Million
59,726 New
59,726 $780,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.34B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.